☆ 4.4 Letter

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results

ACTA ONCOLOGICA (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib

Silvia Bonfiglio et al.

Blood Advances (2023)

Add to Collection

Article Oncology

Precision diagnostics in lymphomas-Recent developments and future directions

Larry Mansouri et al.

Summary: Genetics plays a crucial role in the clinical diagnostics of lymphomas, helping to subclassify the disease and stratify patient risk. Recent advancements in high-throughput sequencing technologies have provided a detailed understanding of the genomic landscape of various lymphoma entities, revealing a diverse genetic background. These studies have improved our understanding of lymphoma ontogeny and evolution and have identified potential genetic markers that can enhance lymphoma diagnostics and prognostication. However, the number of gene mutations with predictive impact for treatment selection remains limited. This review highlights clinically relevant diagnostic, prognostic, and predictive markers in lymphomas and discusses the potential of comprehensive genomic characterization for precision diagnostics and tailored therapy strategies.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Hematology

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo et al.

Summary: Since 1994, the classification of lymphoid neoplasms has been continuously updated through international efforts, with recent progress driven by genomic studies. This proposal presents the International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors, which has refined diagnostic criteria and incorporated new insights from genomics.

BLOOD (2022)

Add to Collection

Review Medicine, General & Internal

Application of precision medicine in clinical routine in haematology-Challenges and opportunities

Tove Wasterlid et al.

Summary: Precision medicine is improving patient care in cancer by utilizing specific genetic knowledge for accurate diagnosis and treatment choices. However, the complex genetic landscape of hematological malignancies poses challenges for implementing precision medicine.

JOURNAL OF INTERNAL MEDICINE (2022)

Add to Collection

Review Oncology

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL

Andreas Agathangelidis et al.

Summary: The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is critical for assessing prognosis and responses to therapy in patients with chronic lymphocytic leukemia (CLL). Immunogenetic analysis in CLL has also revealed distinct subsets of patients based on (quasi)identical B cell receptor immunoglobulin (BcR IG), which display consistent biology, clinical presentation, and outcome. As a cornerstone for accurate risk stratification and clinical decision making, immunogenetic analysis in CLL requires robust methodologies, including next generation sequencing (NGS).

LEUKEMIA (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

Add to Collection

Article Genetics & Heredity

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Binyamin A. Knisbacher et al.

Summary: This study identifies genetic drivers and molecular subtypes associated with clinical outcomes in chronic lymphocytic leukemia (CLL) through genomic, transcriptomic, and epigenomic analysis. The findings provide fresh insights into the oncogenesis and prognostication of CLL.

NATURE GENETICS (2022)

Add to Collection

Article Hematology

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Eric J. Duncavage et al.

Summary: Myeloid neoplasms and acute leukemias are caused by somatic gene mutations that drive the clonal expansion of hematopoietic cells. Genomic characterization plays a crucial role in diagnosis, risk assessment, and clinical decision making. Conventional cytogenetics has been the main method for genomic testing, but recent advances in sequencing technology allow for more accurate detection of somatic mutations. Whole-genome sequencing shows potential as a replacement for traditional methods in patients with myeloid neoplasms, providing rapid and comprehensive genomic profiling.

BLOOD (2022)

Add to Collection

Article Hematology

Genomic profiling for clinical decision making in lymphoid neoplasms

Laurence de Leval et al.

Summary: With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. However, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper discusses how established and newly developed molecular testing technologies complement clinical diagnoses and contribute to refining diagnosis, risk stratification, and therapy prediction for lymphoid neoplasms. Future methods such as whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling are likely to become important tools for implementing precision medicine approaches in clinical decision making for lymphoid malignancies.

BLOOD (2022)

Add to Collection

Correction Genetics & Heredity

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC) (vol 24, pg 986, 2022)

Peter Horak et al.

GENETICS IN MEDICINE (2022)

Add to Collection

Article Hematology

Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study

Vincent Camus et al.

Summary: The study demonstrates the significance of ctDNA analysis as a liquid biopsy and minimal residual disease tool in the management of cHL patients. By using a targeted NGS panel for fast analysis and monitoring the changes in ctDNA after chemotherapy, it helps to assess early treatment response and genetic features of cHL.

HAEMATOLOGICA (2021)

Add to Collection

Article Hematology

Mutational landscape of gray zone lymphoma

Clementine Sarkozy et al.

Summary: The mutational landscape of gray zone lymphoma (GZL) differs between cases with and without thymic niche involvement, showing distinct patterns related to apoptosis defects and BCL2/BCL6 rearrangements, respectively. Additionally, poly-EBV-L cases exhibit a unique mutational profile with STAT3 mutations and lower coding mutation load compared to EBV- GZL. These findings suggest common cell of origin and disease evolution among GZL with thymic presentation and related anterior mediastinal lymphomas.

BLOOD (2021)

Add to Collection

Article Oncology

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Wyndham H. Wilson et al.

Summary: In younger patients with non-GCB DLBCL, the addition of ibrutinib to R-CHOP chemotherapy improves survival rates, particularly in patients with MCD and N1 subtypes. This study provides mechanistic understanding of the benefit of ibrutinib in this patient population.

CANCER CELL (2021)

Add to Collection

Article Oncology

Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Alfredo Rivas-Delgado et al.

Summary: The study analyzed the utility of cfDNA in DLBCL patients to determine mutational profile and tumor burden. It found that higher levels of ctDNA were associated with clinical parameters and treatment response in DLBCL patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Hematology

Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study

Sara Ekberg et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Letter Biotechnology & Applied Microbiology

The nf-core framework for community-curated bioinformatics pipelines

Philip A. Ewels et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection

Article Oncology

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

George W. Wright et al.

CANCER CELL (2020)

Add to Collection

Letter Biochemistry & Molecular Biology

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

David Tamborero et al.

NATURE MEDICINE (2020)

Add to Collection

Article Hematology

Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia

Torsten Haferlach

HEMATOLOGY REPORTS (2020)

Add to Collection

Article Hematology

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Valeria Spina et al.

BLOOD (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Bjoern Chapuy et al.

NATURE MEDICINE (2018)

Add to Collection

Review Hematology

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics

Elias Campo et al.

HAEMATOLOGICA (2018)

Add to Collection

Review Hematology

Redirecting T cells to hematological malignancies with bispecific antibodies

Mireya Paulina Velasquez et al.

BLOOD (2018)

Add to Collection

Article Oncology

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

A. Hochhaus et al.

LEUKEMIA (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Diffuse large B-cell lymphoma genotyping on the liquid biopsy

Davide Rossi et al.

BLOOD (2017)

Add to Collection

Article Oncology

Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life

Mans Stefansson et al.

ACTA ONCOLOGICA (2016)

Add to Collection

Review Hematology

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

Richard Rosenquist et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Cell Biology

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

Florian Scherer et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

Add to Collection

Review Hematology

Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond

Richard Rosenquist et al.

HAEMATOLOGICA (2016)

Add to Collection

Article Hematology

Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib

John C. Byrd et al.

BLOOD (2015)

Add to Collection

Article Genetics & Heredity

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Sue Richards et al.

GENETICS IN MEDICINE (2015)

Add to Collection

Article Oncology

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.